Effectiveness Of Antiplatelet Therapy In Patients With Thrombophilia Gene Mutations

Authors

  • Kurbonova Zumrad Chutbayevna, Babadzhanova Shaira Agzamovna, Qurbanova Gavhar Chutbayevna, Nodirzhanova Zulfiaxon Nodirjon qizi Author

DOI:

https://doi.org/10.64149/J.Ver.8.20s.120-128

Keywords:

Coronavirus Infection, Genetic Mutations, Thrombophilia Genes, Covid-19, Platelet Activity, Antiplatelet Therapy.

Abstract

In mild coronavirus infection, the significance of genetic mutations predisposing to thrombophilia was not confirmed. However, in moderate and severe cases, an un-favorable genotype of the MTHFR 677 C>T (rs1801133) gene and the MTR 5p15.31 66 A>G (rs1801394) gene was significantly more common. The high-risk homozygous mutation of thrombophilia genes was observed only in patients with severe COVID-19, with the predominant genotype being the mutant G/G genotype of the MTR 5p15.31 66 A>G (rs1801394) gene in 23 cases (67.65%). In severe coronavirus infection with a homozygous mutation, the effectiveness of antiplatelet therapy was observed in 3-4 months

Downloads

Published

2025-12-23

Issue

Vol. 8 No. 20s (2025): Vascular & Endovascular Review

Section

Articles

How to Cite

Effectiveness Of Antiplatelet Therapy In Patients With Thrombophilia Gene Mutations. (2025). Vascular and Endovascular Review, 8(20s), 120-128. https://doi.org/10.64149/J.Ver.8.20s.120-128